Compare CWD & IMNN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CWD | IMNN |
|---|---|---|
| Founded | 2009 | 1982 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.6M | 5.1M |
| IPO Year | 2022 | 2000 |
| Metric | CWD | IMNN |
|---|---|---|
| Price | $0.36 | $0.54 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $15.20 |
| AVG Volume (30 Days) | 91.4K | ★ 133.1K |
| Earning Date | 11-12-2026 | 11-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $20,097,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $19.16 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.33 | $0.50 |
| 52 Week High | $2.57 | $4.35 |
| Indicator | CWD | IMNN |
|---|---|---|
| Relative Strength Index (RSI) | 35.56 | 23.75 |
| Support Level | N/A | $0.50 |
| Resistance Level | $0.50 | $1.28 |
| Average True Range (ATR) | 0.04 | 0.10 |
| MACD | -0.00 | -0.01 |
| Stochastic Oscillator | 21.58 | 9.96 |
CaliberCos Inc is an asset management firm investing across real and digital assets. It sponsors and manages private real estate investment funds and maintains a digital asset treasury approach focused on blockchain infrastructure assets. The company's activities are supported by transaction and advisory services, including development and construction management, acquisition and disposition services, brokerage, and fund formation services. The company operates through one reportable segment. It generates the majority of its revenue in the form of asset management fee revenues and performance allocations.
Imunon Inc is a clinical-stage biotechnology company focused on advancing a portfolio of treatments that harness the body's natural mechanisms to generate safe, effective and durable responses across a broad array of human diseases, constituting a differentiating approach from conventional therapies. It is developing its non-viral DNA technology across its modalities. The first modality, TheraPlas, is developed for the coding of proteins and cytokines in the treatment of solid tumors. The second modality, PlaCCine, is developed for the coding of viral antigens that can elicit an immunological response. The company's clinical program, IMNN-001, is a DNA-based immunotherapy for the localized treatment of ovarian cancer.